Compile Data Set for Download or QSAR
Report error Found 16 Enz. Inhib. hit(s) with all data for entry = 1258
TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314067(US9610264, Compound 4)
Affinity DataIC50: 0.270nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314059(US9610264, Compound 1)
Affinity DataIC50: 0.330nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314070(US9610264, Compound 6)
Affinity DataIC50: 0.460nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314068(US9610264, Compound 5)
Affinity DataIC50: 0.610nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314068(US9610264, Compound 5)
Affinity DataIC50: 0.640nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314065(US9610264, Compound 2)
Affinity DataIC50: 0.890nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314071(US9610264, Compound 7)
Affinity DataIC50: 0.980nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314072(US9610264, Compound 8)
Affinity DataIC50: 1.23nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314074(US9610264, Compound 9)
Affinity DataIC50: 1.53nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314075(US9610264, Compound 10)
Affinity DataIC50: 1.64nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314077(US9610264, Compound 11)
Affinity DataIC50: 2.19nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314078(US9610264, Compound 12)
Affinity DataIC50: 2.45nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314079(US9610264, Compound 14)
Affinity DataIC50: 2.64nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314080(US9610264, Compound 13)
Affinity DataIC50: 2.80nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314081(US9610264, Compound 15)
Affinity DataIC50: 4.67nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent

TargetIntegrin alpha-4/beta-7(Human)
Kflp Biotech

US Patent
LigandPNGBDBM314066(US9610264, Compound 3)
Affinity DataIC50: 19.2nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
Go to US Patent